Novartis burnishes Zolgensma data in presymptomatic patients as Roche’s Evrysdi continues eating away at the SMA pie

With sales slowing and Roche’s Evrysdi hot on its tail, Novartis’ Zolgensma for spinal muscular atrophy is seeking to build a stable of data in presymptomatic patients to give it a potential new edge. On Friday, the Swiss biopharma teased out some of the first such results.

Zolgensma met its...

Click to view original post